엘브리지

PRODUCT

Prescription Drugs

Klimaktoplan® Tablets

Non-hormonal menopausal prescription drug
  • · Form Grey cylinder shaped tablets
  • · Active Ingredients in 1 tablet (250 mg)
    Active Ingredients :
    Sanguinaria trituration D6...........25mg
    Ignatia trituration D3...........25mg
    Sepia trituration D2...........25mg
    Cimicifuga trituration D2...........25mg
    Additives (animal-derived) : Lactose monohydrate (cow, milk)
    Other additives : Magnesium stearate, Wheat starch
  • · Effect Improvement of the following symptoms caused by female menopausal disorders : Hot flashes, sweating, palpitations, anxiety, insomnia, depression, excitement
  • · Dosage Take 1 tablet, 3 times a day at the beginning of usage. If symptoms improve, reduce the number of doses per day. Take 30 minutes before or 30 minutes after meals. It can be taken by slowly dissolving in the mouth.
  • · Package unit 100 tablets(20 tablets / PTPx5)
  • · Storage Method 15-25℃, air-tight container
  • · Expiration 48 months from the date of manufacture
  • · Manufacturer Manufacture Requester : DHU-Arzneimittel GmbH & Co. KG (Germany)
    Manufacturer : Dr. Willmar Schwabe GmbH & Co. KG (Germany)
  • · Importer Lbridge Co., Ltd.
    #301 SK V1 Center, 11 Dangsan-ro 41-Gil, Yeongdeungpo-gu, Seoul
    Tel. 02-6121-8300 / Fax. 02-6121-8301

Precautions for use

1. Do not administer to the following patients

  • 1) patients who are hypersensitive to the ingredients of this drug

2. Administer carefully to the following patients

  • 1) This drug contains lactose and should not be used in patients with genetic problems of galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption.
  • 2) This drug contains wheat starch, so patients with celiac disease need to be careful when taking.

3. Adverse reactions

  • 1) Hypersensitivity may be caused to the ingredient of this drug
  • 2) Depending on the patient, nosebleeds may occur and menstruation may occur again. If symptoms occur, stop taking this drug and consult a doctor or pharmacist.
  • 3) Domestic post-marketing survey
    - According to the post-marketing results of 1219 patients in Korea for 4 years, the incidence of adverse events was 4.02% (49 patients / 1219 patients, 55 cases). The drug adverse reaction expression rate was 1.48% (18/1219 patients, 19 cases), menstrual disorder 0.66% (8/1219 patients, 8 cases), headache 0.25% (3/1219 patients, 3 cases), breast congestion 0.16% ( 2/1/1219, two), itching 0.16% (two / 1219, two), swelling, breast pain, nipple pain, ringworm 0.08% (one / 1219, one) There was no significant adverse drug reaction.
    - There were 11 unexpected adverse reactions, including 3 headaches, 2 breast congestion, 2 itching, swelling, breast pain, nipple pain, and ringworm. There were no significant and unexpected adverse drug reactions.

4. General precaution

  • If symptoms do not improve after 12 weeks of taking, stop taking this drug and consult a doctor or pharmacist.

5. Interaction

  • Interaction with other drugs has not been identified.

6. Administration to pregnant and lactating women

  • Do not use during pregnancy and lactation period.

7. Storage and handling precautions

  • 1) keep out of reach of children
  • 2) avoid direct sunlight and store in a cool place of 15~25℃
  • 3) Taking medicine out of its original container and storing it in another container may cause accidents related to drug misuse or deterioration of drug quality.

LB Healthcare Privacy Policy

LB Healthcare rejects the unauthorized collection of email addresses.

LB Healthcare Legal Notice


info@lbifamily.com
02-6121-8300

Personal Information Infringement Report Center(118) http://www.118.or.kr

Supreme Prosecutors ' Office(02-3480-2000) http://www.spo.go.kr

Cyber Terror Response Center(02-393-9112) http://www.ctrc.go.kr 

Other

Domestic

International